Company Legal Name
Latest Valuation
Founded Year
Headquarter
Alloy Therapeutics operates a comprehensive drug discovery platform specializing in antibody, T-cell receptor (TCR) mimic, and oligonucleotide therapeutics development. Founded in 2017 and headquartered in Boston, the company provides integrated discovery services that span from target identification through lead optimization. Alloy's platform combines proprietary technologies with established methodologies to accelerate therapeutic development timelines for pharmaceutical partners and internal programs. The company's multidisciplinary approach addresses critical bottlenecks in drug discovery across multiple therapeutic modalities. Alloy continues to expand its platform capabilities while building a diverse pipeline of novel therapeutic candidates, positioning itself as a strategic partner for biopharmaceutical companies seeking efficient drug discovery solutions.
Revenue & Revenue Growth Share
Revenue
Revenue Growth
Available in most regions; subject to local regulations.
Open to non-accredited investors with KYC/AML compliance. U.S. investors must meet SEC requirements.
$10 per token, enabling fractionalized access to Pre-IPO shares.
Mandatory identity (KYC) and proof of funds checks.
Variable, applied to investment amounts.
Charged on realized profits.
Tokens may be locked for 6–12 months; resale depends on secondary market liquidity.
Prices reflect past funding rounds, not guaranteed future value.
Biotech depends on regulatory approvals; fintech faces evolving digital asset rules.
Blockchain or custodian issues could delay transfers or verification.
Changing laws may affect tradability or taxation.
